IJC Heart and Vasculature最新文献

{"title":"Effects of pulmonary endarterectomy and balloon pulmonary angioplasty in older adults with chronic thromboembolic pulmonary hypertension: A sub-analysis of the CTEPH AC registry","authors":"Jun Yamashita ,&nbsp;Hitoshi Ogino ,&nbsp;Kohei Masaki ,&nbsp;Yu Taniguchi ,&nbsp;Shiro Adachi ,&nbsp;Takumi Inami ,&nbsp;Kazuya Hosokawa ,&nbsp;Ichizo Tsujino ,&nbsp;Nobuhiro Yaoita ,&nbsp;Masaru Hatano ,&nbsp;Nobutaka Ikeda ,&nbsp;Nobuhiro Tanabe ,&nbsp;Hiroto Shimokawahara ,&nbsp;Kayoko Kubota ,&nbsp;Ayako Shigeta ,&nbsp;Koshin Horimoto ,&nbsp;Yoshito Ogihara ,&nbsp;Yoshihiro Dohi ,&nbsp;Takahiro Hiraide ,&nbsp;Takashi Kawakami ,&nbsp;Kohtaro Abe","doi":"10.1016/j.ijcha.2025.101751","DOIUrl":"10.1016/j.ijcha.2025.101751","url":null,"abstract":"<div><h3>Background</h3><div>Invasive treatments for chronic thromboembolic pulmonary hypertension (CTEPH) include pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA). Both PEA and BPA demonstrate significant benefits for symptom relief, hemodynamic improvement, and overall patient outcomes. However, evidence of their efficacy in older adults remains limited. This study aimed to evaluate treatment efficacy—including exercise tolerance, hemodynamics, functional status—and clinical outcomes in CTEPH patients aged ≥70 years who underwent PEA or BPA.</div></div><div><h3>Methods</h3><div>Among 1,527 patients in the CTEPH AntiCoagulants Registry, we selected those aged 70 years or older, including 25 who underwent PEA during follow-up and 210 who received BPA. We evaluated the World Health Organization functional class (WHO FC), a measure of subjective symptoms, along with exercise capacity, hemodynamic parameters, and clinical outcomes.</div></div><div><h3>Results</h3><div>At baseline, BPA patients were older (P = 0.003) and tended to have lower body weight (P = 0.069) than those undergoing PEA. At a median follow-up of ∼2 years, BPA significantly improved six-minute walk distance and cardiac index, and reduced mean pulmonary artery pressure and pulmonary vascular resistance, with effects comparable to PEA after adjusting for age, sex, and body mass index (all adjusted P &gt; 0.10). However, improvement in WHO FC was more frequent with BPA and became significant after covariate adjustment (adjusted P = 0.035). Adverse event rates were infrequent and similar between the two groups (all P &gt; 0.10).</div></div><div><h3>Conclusions</h3><div>In adults aged ≥ 70 years with CTEPH, BPA improved hemodynamics, exercise capacity, and outcomes comparable to PEA, but with greater WHO FC improvement. Further randomized trials in older adults are warranted.</div></div><div><h3>Clinical trial registration number</h3><div>UMIN Clinical Trials Registry (identifier UMIN 000033784).</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101751"},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in hospitalisation and healthcare utilisation for patients with atrial fibrillation Middeldorp et al. Sex differences in healthcare utilisation and AF","authors":"Melissa E. Middeldorp ,&nbsp;Colinda van Deutekom ,&nbsp;Liann I. Weil ,&nbsp;Isabelle C. Van Gelder ,&nbsp;Ursula W. De Ruijter ,&nbsp;Patrick T. Jeurissen ,&nbsp;Emelia J. Benjamin ,&nbsp;Barbara C. van Munster ,&nbsp;Michiel Rienstra","doi":"10.1016/j.ijcha.2025.101748","DOIUrl":"10.1016/j.ijcha.2025.101748","url":null,"abstract":"<div><h3>Background</h3><div>There is limited data on sex differences in healthcare utilization among patients with atrial fibrillation (AF). This study aimed to assess the association of sex and age on healthcare utilization in AF patients.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of electronic health records from three hospitals in the Netherlands, including all patients ≥ 18 years with at least one healthcare encounter (outpatient, emergency visit, or inpatient stay). AF diagnoses were identified using ICD-10 codes linked with the Dutch Hospital Data Clinical Classification Software.</div></div><div><h3>Results</h3><div>Of 226,991 patients, 5127 (2.3 %) had AF (44 % females, mean age 68 ± 12 years). There were no sex differences in outpatient, emergency, or inpatient visits overall. However, females aged 18–59 had more outpatient visits compared to males (6.1 ± 7.9 vs 4.8 ± 5.2, p = 0.001). In contrast, females aged ≥ 75 had fewer outpatient visits (7.2 vs 8.4, p &lt; 0.001) and inpatient days (4.8 vs 5.8, p = 0.027) compared to males. After multivariable adjustment, both sexes aged ≥ 75 had increased risks of inpatient stays (Females: OR 2.53, 95 % CI 2.30–2.78; Males: OR 1.49, 95 % CI 1.46–1.62) and emergency visits (Females: OR 2.14, 95 % CI 1.94–2.35; Males: OR 1.13, 95 % CI 1.03–1.24). Significant interactions between sex and age were found, with females having higher odds of inpatient days (OR 1.99, p &lt; 0.001) and emergency visits (OR 1.23, p &lt; 0.001) compared to males.</div></div><div><h3>Conclusion</h3><div>While no overall sex differences in healthcare utilization were found, significant age-related differences were observed, with females having higher hospital utilization rates, particularly for inpatient stays and emergency visits.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101748"},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OCT and angiography-derived vFFR post-PCI in the assessment of anatomical and physiological optimization","authors":"Ioannis Skalidis ,&nbsp;Livio D’Angelo ,&nbsp;Thomas Hovasse ,&nbsp;Philippe Garot ,&nbsp;Mariama Akodad","doi":"10.1016/j.ijcha.2025.101744","DOIUrl":"10.1016/j.ijcha.2025.101744","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101744"},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid dysfunction and pulmonary arterial hypertension: A bidirectional mendelian randomization study","authors":"Gongli Pang ,&nbsp;Xiaoxia Wang ,&nbsp;Ru Zhao ,&nbsp;Peng Yang ,&nbsp;Jie Chen ,&nbsp;Yanqing Guo ,&nbsp;Chendi Liang","doi":"10.1016/j.ijcha.2025.101747","DOIUrl":"10.1016/j.ijcha.2025.101747","url":null,"abstract":"<div><h3>Objective</h3><div>Thyroid dysfunction can cause several cardiovascular diseases. Studies have suggested a link between thyroid dysfunction and an increased risk of Pulmonary Arterial Hypertension (PAH). However, the causal association between this link is unknown. The aim of this study was to investigate the causal association between thyroid dysfunction and PAH using bidirectional<!--> <!-->two-sample Mendelian Randomization (MR) analysis.</div></div><div><h3>Method</h3><div>Thyroid dysfunction (Free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), hyperthyroidism and hypothyroidism) and PAH were respectively used as exposure and outcome factors. The bidirectional causal association between thyroid dysfunction and PAH was analyzed by using Inverse Variance Weighting (IVW), MR-Egger regression (MR-Egger), and Weighted Median (WM) methods. Cochran’s Q test was used to analyze the heterogeneity among single nucleotide polymorphisms (SNPs). The intercept term of MR-Egger regression and MR-PRESSO were used to analyze horizontal pleiotropy. The effect of single SNP on the MR analysis results was analyzed by leave-one-out method.</div></div><div><h3>Results</h3><div>The IVW showed that hypothyroidism could increase the risk of PAH (OR = 1.485, 95 % CI [1.051, 2.100], P = 0.025), while FT3, FT4, TSH and hyperthyroidism were not associated with the risk of PAH. Furthermore, we found no evidence of reverse causal association between PAH and thyroid dysfunction.</div></div><div><h3>Conclusion</h3><div>Our study found that hypothyroidism is causally associated with an increased risk of PAH. However, further investigations are still needed to illustrate the connection between thyroid dysfunction and PAH.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101747"},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous iron in heart failure: still no prognostic impact, but questions remain","authors":"Ibrahim El-Battrawy ,&nbsp;Nazha Hamdani ,&nbsp;Mohammad Abumayyaleh ,&nbsp;Ibrahim Akin","doi":"10.1016/j.ijcha.2025.101746","DOIUrl":"10.1016/j.ijcha.2025.101746","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101746"},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between DOACs and warfarin for left atrial thrombus in atrial fibrillation patients","authors":"Akihiro Sunaga ,&nbsp;Daisaku Nakatani ,&nbsp;Katsuki Okada ,&nbsp;Hirota Kida ,&nbsp;Yuki Matsuoka ,&nbsp;Daisuke Sakamoto ,&nbsp;Tetsuhisa Kitamura ,&nbsp;Nobuaki Tanaka ,&nbsp;Yasuyuki Egami ,&nbsp;Masaharu Masuda ,&nbsp;Tetsuya Watanabe ,&nbsp;Hitoshi Minamiguchi ,&nbsp;Takafumi Oka ,&nbsp;Koichi Inoue ,&nbsp;Shungo Hikoso ,&nbsp;Yohei Sotomi ,&nbsp;Yasushi Sakata","doi":"10.1016/j.ijcha.2025.101745","DOIUrl":"10.1016/j.ijcha.2025.101745","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) is a major risk factor for thromboembolic events, with left atrial thrombus (LAT) formation occurring despite oral anticoagulant (OAC) therapy in some patients. Direct oral anticoagulants (DOACs) have demonstrated efficacy in preventing thrombosis; however, their role in LAT resolution compared to warfarin remains unclear.</div></div><div><h3>Methods</h3><div>This retrospective, multicenter study analyzed 260 AF patients with transesophageal echocardiography (TEE)-confirmed LAT among 17,436 AF patients who underwent TEE. Patients were categorized into DOAC and warfarin groups. LAT resolution, ischemic stroke/systemic embolism, major bleeding, and all-cause death were evaluated. The warfarin group was further stratified by time in therapeutic range (TTR) (&lt;60 % and ≥ 60 %), and the DOAC group by dose (standard and low).</div></div><div><h3>Results</h3><div>During a median follow-up of 386 [367, 413] days, LAT resolution was achieved in 62 % of patients, significantly higher in the DOAC group (74 % vs. 54 %, P = 0.001). Standard-dose DOACs had the highest resolution rates, while TTR &lt; 60 % had the lowest (79 % vs. 49 %). DOACs were independently associated with higher LAT resolution (OR = 2.91 [1.32–6.38], P = 0.008) and fewer bleeding events (OR = 0.26 [0.08–0.80], P = 0.019).</div></div><div><h3>Conclusions</h3><div>DOAC therapy was associated with higher LAT resolution rates and showed a fewer bleeding events compared to warfarin. DOACs may serve as first-line therapy for LAT.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101745"},"PeriodicalIF":2.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can TAVI be performed without on-site cardiac surgery?","authors":"V. Lodo ,&nbsp;C. Barbero ,&nbsp;S. Salizzoni ,&nbsp;E. Zingarelli ,&nbsp;M.La Torre ,&nbsp;Italiano G. Enrico ,&nbsp;P. Centofanti ,&nbsp;M. Rinaldi","doi":"10.1016/j.ijcha.2025.101736","DOIUrl":"10.1016/j.ijcha.2025.101736","url":null,"abstract":"<div><h3>Introduction</h3><div>Aim of this analysis in to assess the prevalence and post-procedural outcomes of surgical bailout during transcatheter aortic valve implantation (TAVI).</div></div><div><h3>Methods</h3><div>Patients undergoing TAVI from September 2017 to March 2023 were enrolled from two high volume centers. All the procedures were performed with on-site cardiac surgery, but especially the scrubbed cardiac surgeon. The primary endpoint was in-hospital mortality of TAVI patients after emergent cardiac surgery (ECS). Secondary endpoints were intra-operative and 1-year mortality, and post-procedural complications such as acute kidney injury (AKI), stroke, myocardial infarction (MI), conduction abnormalities, need for inotropic support and intensive care unit (ICU) and in- hospital length of stay.</div></div><div><h3>Results</h3><div>A total of 1347 consecutive patients underwent transfemoral TAVI. Ten patients (0.74 %), representing the study population, reported intra-procedural complications requiring ECS: seven patients received a self-expandable prosthesis; three patients received a balloon expandable prosthesis. Indications for ECS included: type A dissection (n = 2), aortic annulus rupture (n = 1), left(n = 1) and right (n = 2) ventricle perforation, mitral valve apparatus damage (n = 2), prosthesis embolization (n = 2). Four patients required post-operative inotropic support. One case of minor stroke and one case of AKI (grade III) were reported. Three patients developed a post procedural left bundle branch block (LBBB). Median ICU and hospital length-of-stay were 4.5 (2–7.75) days and 14 (8–22) days, respectively. One case of in-hospital mortality was reported.</div></div><div><h3>Conclusions</h3><div>The on-site cardiac surgery, with the scrubbed heart surgeon, represents a life-saving resource for TAVI centers in case of ECS, and it is essential to achieve low-rate in-hospital mortality.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101736"},"PeriodicalIF":2.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144571690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease – a secondary analysis of the randomized TWENTE trials","authors":"Daphne van Vliet ,&nbsp;Tineke H. Pinxterhuis ,&nbsp;Eline H. Ploumen ,&nbsp;Marlies M. Kok ,&nbsp;Rosaly A. Buiten ,&nbsp;Paolo Zocca ,&nbsp;Ariel Roguin ,&nbsp;Carl E. Schotborgh ,&nbsp;Rutger L. Anthonio ,&nbsp;Peter W. Danse ,&nbsp;Edouard Benit ,&nbsp;Adel Aminian ,&nbsp;Carine J.M. Doggen ,&nbsp;Clemens von Birgelen","doi":"10.1016/j.ijcha.2025.101741","DOIUrl":"10.1016/j.ijcha.2025.101741","url":null,"abstract":"<div><h3>Background</h3><div>The presence of polyvascular atherosclerotic disease is associated with a high-risk of adverse events following percutaneous coronary intervention (PCI). As the extent to which the presence of diabetes further increases this elevated risk is unclear, based on current literature, we sought to assess the long-term outcome after PCI in patients with polyvascular disease, comparing those with and without diabetes.</div></div><div><h3>Methods</h3><div>The current study population consists of patients with known polyvascular disease, identified from a pooled patient-level database of 4 PCI trials in all-comers treated with new-generation drug-eluting stents; no exclusion criteria were set. The main composite endpoint was major adverse cardiac event (MACE: any myocardial infarction, emergent coronary bypass surgery, clinically indicated target lesion revascularization, or all-cause mortality).</div></div><div><h3>Results</h3><div>695 patients had polyvascular disease of whom 208(29.9 %) had diabetes. Patients with diabetes were older, had a higher body-mass-index, and had a higher prevalence of hypertension than those without diabetes. At 3-year follow-up, the incidence of MACE was significantly higher in polyvascular disease patients with diabetes (24.6 % vs.16.4 %, adj.HR:1.49, 95 %CI:1.05–2.12, p = 0.03), in particular insulin-treated patients, and was primarily attributable to a disparity in all-cause mortality which was more than twice as high in patients with diabetes (15.4 % vs.7.2 %, p &lt; 0.001). Furthermore, the risk of repeated target vessel revascularization was higher in patients with diabetes (12.0 % vs7.0 %, adj.HR:1.88, 95 %CI:1.12–3.16, p = 0.02).</div></div><div><h3>Conclusions</h3><div>In the high-risk population of PCI patients with polyvascular disease, the presence of diabetes represents a profoundly significant additional risk factor at long-term follow-up, associated with significantly higher adverse event risks.</div><div><strong>Trial registration:</strong> <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> NCT01066650 NCT0133170 NCT01674803<!--> <!-->NCT02508714.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101741"},"PeriodicalIF":2.5,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative flow ratio after CTO PCI as a predictor of long-term outcomes","authors":"Ioannis Skalidis,&nbsp;Thierry Unterseeh,&nbsp;Francesca Sanguineti,&nbsp;Stephane Champagne,&nbsp;Neila Sayah","doi":"10.1016/j.ijcha.2025.101740","DOIUrl":"10.1016/j.ijcha.2025.101740","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101740"},"PeriodicalIF":2.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response","authors":"Laura Ueberham ,&nbsp;Theresa Kluge ,&nbsp;Konrad Latuscynski ,&nbsp;Hans Ebbinghaus ,&nbsp;Joanna Jozwiak-Nozdrzykowska ,&nbsp;Stephan Renziehausen ,&nbsp;Annika Reuser ,&nbsp;Kerstin Bode ,&nbsp;Regine Kluge ,&nbsp;Ulrich Laufs ,&nbsp;Osama Sabri ,&nbsp;Borislav Dinov","doi":"10.1016/j.ijcha.2025.101737","DOIUrl":"10.1016/j.ijcha.2025.101737","url":null,"abstract":"<div><h3>Background</h3><div>¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) is recommended for diagnosis and evaluation of therapy in patients with cardiac sarcoidosis (CS).</div></div><div><h3>Objectives</h3><div>FDG uptake parameters were investigated semi-quantitatively in biopsy-proven CS at time of diagnosis (CSD) and during immunosuppressive therapy (CST) and in controls.</div></div><div><h3>Methods</h3><div>We studied 11 patients with endomyocardial biopsy-proven CS and 15 controls. FDG uptake was assessed as myocardial-to-background ratio (MBR) of standardized uptake values in the 17-segment model and right ventricle in relation to clinical baseline parameters and changes during follow-up (FU).</div></div><div><h3>Results</h3><div>MBRs per cardiac segment in controls were below 2.1 in all control patients. In CSD, median MBR was 2.4 (IQR 1.3; 4.0), highest septal and anterobasal. In CST, median MBR was 1.5 (IQR 1.1; 1.7) with a significant reduction of mean MBRs from baseline per cardiac segment (z −9.5, p &lt; 0.001). Patients with clinical progress showed higher MBRs and more affected cardiac segments before therapy (n = 2, MBR 4.3 ± 3.0, 18.0 ± 0) than patients with stable disease (n = 5, MBR 2.8 ± 1.2, 14.4 ± 4.6) or clinical improvement (n = 4, MBR 2.6 ± 2.5, 8.0 ± 7.4, p = n.s.) Applying a new score based on mean MBR times number of involved segments showed highest values in patients with clinical progression.</div></div><div><h3>Conclusion</h3><div>MBRs per cardiac segment can be used as a semiquantitative tool to evaluate FDG uptake in patients with CS with a cut-off ≥2.1 for relevant pathologic uptake. The clinical course may correlate with the number of affected cardiac segments and the MBRs per segment.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101737"},"PeriodicalIF":2.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}